158 related articles for article (PubMed ID: 31373632)
1. Different factors underlie recurrent and de novo organ involvement in immunoglobulin G4-related disease.
Mizushima I; Tsuge S; Fujisawa Y; Hara S; Suzuki F; Ito K; Fujii H; Yamada K; Kawano M
Rheumatology (Oxford); 2020 Mar; 59(3):513-518. PubMed ID: 31373632
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
3. Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up.
Liu Z; Peng Y; Li J; Lu H; Peng L; Zhou J; Zhou S; Huang C; Wang M; Zhu L; Chen H; Wang L; Fei Y; Zhao Y; Zeng X; Zhang W
J Intern Med; 2022 Jul; 292(1):91-102. PubMed ID: 35419810
[TBL] [Abstract][Full Text] [Related]
4. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse.
Lanzillotta M; Della-Torre E; Milani R; Bozzolo E; Bozzalla-Cassione E; Rovati L; Arcidiacono PG; Partelli S; Falconi M; Ciceri F; Dagna L
Arthritis Res Ther; 2018 Oct; 20(1):222. PubMed ID: 30285841
[TBL] [Abstract][Full Text] [Related]
5. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients.
Wang L; Zhang P; Zhang X; Lin W; Tang H; Li J; Wang M; Liu X; Fei Y; Chen H; Peng L; Zhang L; Lai Y; Zeng X; Li X; Xue H; Zhao Y; Zhang F; Zhang W
Rheumatology (Oxford); 2019 May; 58(5):820-830. PubMed ID: 30561747
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
7. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
[TBL] [Abstract][Full Text] [Related]
8. Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study.
Zhou J; Peng Y; Peng L; Wu D; Li J; Jiang N; Li J; Lu H; Liu Z; Luo X; Teng F; Fei Y; Zhang W; Zhao Y; Zeng X
Arthritis Res Ther; 2020 Oct; 22(1):255. PubMed ID: 33097076
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
10. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients.
Miki M; Fujimori N; Oono T; Kawabe K; Ohno A; Matsumoto K; Teramatsu K; Tachibana Y; Ogawa Y
J Dig Dis; 2019 Mar; 20(3):152-158. PubMed ID: 30701685
[TBL] [Abstract][Full Text] [Related]
11. Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy.
Wang M; Zhang P; Lin W; Fei Y; Chen H; Li J; Zhang L; Zheng W; Li Y; Zeng X; Zhou J; Lai Y; Liu X; Xue H; Cui Y; Zhou L; Zhao J; Zhang W
Arthritis Res Ther; 2019 Feb; 21(1):44. PubMed ID: 30709411
[TBL] [Abstract][Full Text] [Related]
12. Different clinical patterns of IgG4-RD patients with and without eosinophilia.
Zhang X; Zhang P; Li J; He Y; Fei Y; Peng L; Shi Q; Zhang W; Zhao Y
Sci Rep; 2019 Nov; 9(1):16483. PubMed ID: 31712579
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study.
Fukui S; Kawaai S; Nakai T; Suda M; Ikeda Y; Nomura A; Tamaki H; Kishimoto M; Ohde S; Okada M
Rheumatology (Oxford); 2021 Dec; 60(12):5697-5704. PubMed ID: 33723568
[TBL] [Abstract][Full Text] [Related]
14. Serum IgG4 levels at diagnosis can predict unfavorable outcomes of untreated patients with IgG4-related disease.
Mizushima I; Konishi M; Sanada H; Suzuki K; Takeji A; Zoshima T; Hara S; Ito K; Fujii H; Yamada K; Kawano M
Sci Rep; 2021 Jun; 11(1):13341. PubMed ID: 34172819
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical features and outcomes of proliferative, fibrotic, and mixed subtypes of IgG4-related disease: A retrospective cohort study.
Peng L; Zhang X; Zhou J; Li J; Liu Z; Lu H; Peng Y; Fei Y; Zhao Y; Zeng X; Zhang W
Chin Med J (Engl); 2024 Feb; 137(3):303-311. PubMed ID: 37538048
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Clin Rheumatol; 2023 Jan; 42(1):135-143. PubMed ID: 36074221
[TBL] [Abstract][Full Text] [Related]
19. Predictors of disease relapse in IgG4-related disease following rituximab.
Wallace ZS; Mattoo H; Mahajan VS; Kulikova M; Lu L; Deshpande V; Choi HK; Pillai S; Stone JH
Rheumatology (Oxford); 2016 Jun; 55(6):1000-8. PubMed ID: 26888853
[TBL] [Abstract][Full Text] [Related]
20. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.
Shirakashi M; Yoshifuji H; Kodama Y; Chiba T; Yamamoto M; Takahashi H; Uchida K; Okazaki K; Ito T; Kawa S; Yamada K; Kawano M; Hirata S; Tanaka Y; Moriyama M; Nakamura S; Kamisawa T; Matsui S; Tsuboi H; Sumida T; Shibata M; Goto H; Sato Y; Yoshino T; Mimori T
Sci Rep; 2018 Jul; 8(1):10262. PubMed ID: 29980706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
